- Home
- HEPA vs CNSP Comparison
HEPA vs CNSP Comparison
Compare HEPA & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPA
- CNSP
- Stock Information
- Founded
- HEPA 2013
- CNSP 2017
- Country
- HEPA United States
- CNSP United States
- Employees
- HEPA N/A
- CNSP N/A
- Industry
- HEPA Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- HEPA Health Care
- CNSP Health Care
- Exchange
- HEPA Nasdaq
- CNSP Nasdaq
- Market Cap
- HEPA 4.7M
- CNSP 5.4M
- IPO Year
- HEPA N/A
- CNSP 2019
- Fundamental
- Price
- HEPA $0.68
- CNSP $0.11
- Analyst Decision
- HEPA Hold
- CNSP Strong Buy
- Analyst Count
- HEPA 1
- CNSP 1
- Target Price
- HEPA N/A
- CNSP $0.50
- AVG Volume (30 Days)
- HEPA 39.0K
- CNSP 41.4M
- Earning Date
- HEPA 11-26-2024
- CNSP 11-15-2024
- Dividend Yield
- HEPA N/A
- CNSP N/A
- EPS Growth
- HEPA N/A
- CNSP N/A
- EPS
- HEPA N/A
- CNSP N/A
- Revenue
- HEPA N/A
- CNSP N/A
- Revenue This Year
- HEPA N/A
- CNSP N/A
- Revenue Next Year
- HEPA N/A
- CNSP N/A
- P/E Ratio
- HEPA N/A
- CNSP N/A
- Revenue Growth
- HEPA N/A
- CNSP N/A
- 52 Week Low
- HEPA $0.55
- CNSP $0.10
- 52 Week High
- HEPA $4.47
- CNSP $137.50
- Technical
- Relative Strength Index (RSI)
- HEPA 52.88
- CNSP 37.06
- Support Level
- HEPA $0.60
- CNSP $0.10
- Resistance Level
- HEPA $0.68
- CNSP $0.13
- Average True Range (ATR)
- HEPA 0.05
- CNSP 0.02
- MACD
- HEPA 0.00
- CNSP 0.00
- Stochastic Oscillator
- HEPA 87.80
- CNSP 8.50
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.